Lee, Dae Hyun
Chandrasekhar, Sanjay
Jain, Michael D.
Mhaskar, Rahul
Reid, Kayla
Lee, Sae Bom
Corallo, Salvatore
Hidalgo-Vargas, Melanie J.
Kumar, Abhishek
Chavez, Julio
Shah, Bijal
Lazaryan, Aleksandr
Khimani, Farhad
Nishihori, Taiga
Bachmeier, Christina
Faramand, Rawan
Fradley, Michael G.
Jeong, Daniel
Oliveira, Guilherme H.
Locke, Frederick L.
Davila, Marco L
Alomar, Mohammed
Funding for this research was provided by:
University of South Florida (USF GME 2022-01)
Article History
Received: 14 February 2023
Accepted: 20 March 2023
First Online: 1 April 2023
Declarations
:
: This study was approved by the IRB of the University of South Florida (Pro00029257 and Pro00021733).
: N/A.
: A.L.: Consultancy and advisory board for Kadmon/ Sanofi, Humanigen, Avrobio.F.L.L.: Scientific advisory role for A2, Allogene, Amgen, Bluebird Bio, BMS/Celgene, Calibr, Caribou, Cellular Biomedicine group, Daiichi Sankyo, GammaDelta Therapeutics, Iovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana, Takeda, Wugen, Umoja. Research Funding from: Kite Pharma (institutional), Allogene (institutional), CERo Therapeutics (institutional), Novartis (institutional), BlueBird Bio (Institutional), BMS (Institutional), National Cancer Institute, Leukemia and Lymphoma Society. Consulting Role for: Cowen, EcoR1, Emerging Therapy Solutions, Gerson Lehrman Group (GLG).M.J.: Consulting Advisory for: Kite/ Gilead, Novartis, BMS, Myeloid Tx; Research Funding: Incyte, Kite/ Gilead.M.L.D: Consulting fees from Adicet, Bellicum, Capsta, Syncopation, and Synthekine; Stock or stock options with Adaptive Biotechnologies, Adicet, Bellicum Precision Biosciences and Prescient; Receiving licensing fees from Atara and CRISPR.R.F.: Research support from Novartis and Kite/ Gilead.The remaining authors have nothing to disclose.